Laura Dawson MD, FRCPC, FASTRO
Professor, University of Toronto
Radiation Oncologist, Princess Margaret Cancer Centre
Dr. Laura Dawson is a Professor in the Department of Radiation Oncology at the University of Toronto, and a practicing radiation oncologist at the Radiation Medicine Program, Princess Margaret Cancer Centre, in Toronto. She is the multi-disciplinary hepatobiliary cancer and pancreatic cancer site lead for the Princess Margaret Cancer Committee. She is an internationally recognized leader in hepatocellular carcinoma and in oligo-metastases stereotactic body radiation therapy (SBRT). She is the principal investigator of two randomized phase III clinical trials investigating the use of radiation therapy in hepatocellular carcinoma (RTOG1112 and CCTG HE1).
Rachel Goodwin, MSc, MD, FRCPC
Assistant Professor of Medicine,
Faculty of Medicine, University of Ottawa
Dr. Rachel Goodwin graduated from Mount Saint Vincent University with a Bachelor of Science and from the University of Guelph with a Masters of Nutritional Science. She completed medical school and her internal medicine and medical oncology residency at the University of Ottawa. Dr. Goodwin went on to complete a two-year Investigational New Drug Development Fellowship at NCIC Clinical Trial Group at Queen’s University, with a focus on Phase I/Phase II cancer clinical trials.
She is an Assistant Professor in the Faculty of Medicine at the University of Ottawa. Her clinical interests include gastrointestinal cancers, neuroendocrine cancers and new drug development. Dr. Goodwin is an active member of the Canadian Cancer Trials Group where she is New Drug Development Liaison and co-chair for the Colon Disease Site Group.
Brandon Meyers, MSc, MD, FRCPC
Associate Professor, Oncology
Dr. Meyers completed medical school at the University of Ottawa. He then completed at McMaster University post-graduate training in Internal Medicine, and Medical Oncology followed by a fellowship in Gastrointestinal Malignancies. He is an Associate Professor and staff Medical Oncologist at the Juravinski Cancer Centre in Hamilton, Ontario. His gastrointestinal clinical practice primarily focuses on hepatocellular carcinoma. He recently helped develop the Cancer Care Ontario guidelines on the management of advanced hepatocellular carcinoma, and is involved in phase I-III trials examining novel agents for liver cancer. He also collaborates with basic scientists working with animal models of liver cancer. He is a member of the Planning Committee of the Canadian Multidisciplinary HCC Conference.
Vincent Tam, MD, FRCPC
Associate Clinical Professor,
University of Calgary
Dr. Vincent Tam is Associate Clinical Professor at the University of Calgary and a staff medical oncologist at the Tom Baker Cancer Centre. He specializes in the treatment of gastrointestinal malignancies and particularly hepatobiliary cancer. His research interests include clinical trials in hepatobiliary cancer and real world outcomes of HCC patients treated with various systemic therapies.